Mineralys Therapeutics (NASDAQ: MLYS) announced participation in the Goldman Sachs 47th Annual Global Healthcare Conference in Miami, held June 8-10, 2026.
Management will join a fireside chat on Tuesday, June 9, 2026, at 2:40 p.m. ET, with a live webcast available via the company’s investor relations website.
Loading...
Loading translation...
Positive
None.
Negative
None.
News Market Reaction – MLYS
+7.47%
25 alerts
+7.47%Session close to close
+7.1%Peak in 30 hr 19 min
$2.13BMarket Cap
1.3xRel. Volume
In the Jun 9 session, MLYS gained 7.47%, reflecting a notable positive market reaction.
Argus tracked a peak move of +7.1% during that session.
Our momentum scanner triggered 25 alerts that day, indicating elevated trading interest and price volatility.
The stock moved +7.5% in the session following this news. A strong positive reaction aligns with the...
Analysis
The stock moved +7.5% in the session following this news. A strong positive reaction aligns with the company’s pattern of using conference appearances to maintain visibility amid major clinical and financing milestones. With shares trading below the $32.80 200-day moving average and about 50% under the 52-week high of $47.65, sustained gains would need to contend with prior dilution from the recent $150 million offering and historical instances where favorable clinical news was followed by mixed price responses.
New Phase 3 Launch-HTN data on lorundrostat in uncontrolled hypertension with CKD.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Pattern Detected
Recent financing headlines aligned with share price declines, while conference and clinical data announcements have shown mixed or divergent price reactions.
Recent Company History
Over the past few weeks, MLYS has reported multiple events, including a Phase 3 Launch-HTN data presentation (May 30, 2026), participation in the Jefferies Global Healthcare Conference, and a royalty repurchase/financing package involving a $200 million upfront payment and $500 million term loan. An underwritten equity offering of about $150 million followed, which coincided with a 13.14% decline. Today’s Goldman Sachs conference participation fits a pattern of active investor outreach alongside major clinical and financing milestones.
Key Terms
chronic kidney disease, ckd, obstructive sleep apnea, osa, +1 more
5 terms
chronic kidney diseasemedical
"comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea..."
Chronic kidney disease is a long-term, progressive loss of kidney function that reduces the organs’ ability to filter waste, control fluid levels and balance body salts. For investors, CKD matters because it creates sustained demand for tests, drugs, dialysis machines and transplants; advances in treatment or regulatory decisions can meaningfully change revenue prospects for companies—like a car that needs ongoing repairs, it creates predictable, long-term market needs.
ckdmedical
"comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea..."
Chronic kidney disease (CKD) is a long-term condition where the kidneys gradually lose their ability to filter waste and fluids from the blood, like household filters that slowly clog and underperform over time. It matters to investors because CKD drives demand for drugs, medical devices, diagnostics and dialysis services, influences healthcare spending and reimbursement decisions, and creates regulatory or clinical-trial risks and market opportunities across the healthcare sector.
obstructive sleep apneamedical
"comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea (OSA)..."
Obstructive sleep apnea is a common medical condition where the throat repeatedly narrows or closes during sleep, causing short pauses in breathing, drops in blood oxygen and fragmented rest. It matters to investors because it creates ongoing demand for medical devices, diagnostics, treatments and sleep-monitoring services, and it can affect population health, workforce productivity and healthcare spending—like a recurring leak in a system that requires continual repair and monitoring.
osamedical
"chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases..."
Obstructive sleep apnea (OSA) is a common sleep disorder where the upper airway repeatedly narrows or collapses during sleep, causing brief breathing stoppages that fragment rest and raise daytime tiredness and health risks. For investors, OSA creates sustained demand for diagnostic tests, therapy devices, drugs and monitoring services, so changes in clinical data, approvals, or reimbursement can materially affect revenue prospects for companies in the sleep-health sector.
aldosteronemedical
"and other diseases driven by dysregulated aldosterone, today announced that..."
Aldosterone is a hormone made by small glands above the kidneys that helps the body hold on to salt and water and release potassium, functioning like a household thermostat that adjusts fluid levels. It matters to investors because drugs or tests that change or measure aldosterone can alter treatment of high blood pressure, heart failure and kidney disease, affecting sales, trial outcomes and regulatory decisions in related healthcare markets.
RADNOR, Pa., June 08, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, today announced that management will be participating in the Goldman Sachs 47th Annual Global Healthcare Conference being held in Miami on June 8-10, 2026.
Goldman Sachs 47th Annual Global Healthcare Conference
A live webcast of this fireside chat can also be accessed on the “News & Events” page in the Investors section of the Mineralys Therapeutics website.
About Mineralys
Mineralys Therapeutics is a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as CKD, OSA and other diseases driven by dysregulated aldosterone. Its initial product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor. Mineralys is based in Radnor, Pennsylvania, and was founded by Catalys Pacific. For more information, please visit https://mineralystx.com. Follow Mineralys on LinkedIn, Twitter and Bluesky.
When will Mineralys Therapeutics (NASDAQ: MLYS) present at the Goldman Sachs 47th Annual Global Healthcare Conference?
Mineralys Therapeutics will participate in a fireside chat on Tuesday, June 9, 2026, at 2:40 p.m. ET. The appearance occurs during the Goldman Sachs 47th Annual Global Healthcare Conference in Miami, scheduled for June 8-10, 2026.
How can investors access the Mineralys Therapeutics (MLYS) webcast from the Goldman Sachs 2026 healthcare conference?
Investors can access a live webcast of the Mineralys Therapeutics fireside chat through the company’s website. According to the company, it will be available on the Investors section under the “News & Events” page for convenient online viewing.
What is the format of Mineralys Therapeutics’ session at the Goldman Sachs 47th Annual Global Healthcare Conference?
Mineralys Therapeutics will appear in a fireside chat format at the conference. According to the company, the session is scheduled for June 9, 2026, at 2:40 p.m. ET and will also be broadcast via live webcast for investors.
Where is the Goldman Sachs 47th Annual Global Healthcare Conference featuring Mineralys Therapeutics (MLYS) being held?
The Goldman Sachs 47th Annual Global Healthcare Conference featuring Mineralys Therapeutics is being held in Miami. According to the company, its management will participate in a fireside chat session on June 9, 2026, during the June 8-10, 2026 conference.
What does Mineralys Therapeutics focus on as it participates in the Goldman Sachs 2026 healthcare conference?
Mineralys Therapeutics focuses on developing medicines for hypertension and related comorbidities. According to the company, its pipeline targets conditions like chronic kidney disease, obstructive sleep apnea, and other diseases driven by dysregulated aldosterone, which may interest investors following its conference participation.
